Welcome to our dedicated page for Varex Imaging SEC filings (Ticker: VREX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Varex Imaging Corporation (VREX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a publicly traded Nasdaq issuer. Varex designs and manufactures X-ray imaging components and systems for medical, industrial, and security applications, and its filings offer detailed insight into how this business is reflected in its financial statements, risk factors, and governance disclosures.
Through this page, users can review Varex’s periodic reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which present segment information for the Medical and Industrial businesses, revenue composition, gross margin, operating expenses including research and development, and details on capital structure items like long-term debt and convertible notes. These filings also contain management’s discussion and analysis and other disclosures that complement the high-level figures in press releases.
Current reports on Form 8-K document specific material events. For example, a recent 8-K furnished an earnings press release titled “Varex Announces Financial Results for Fourth Quarter and Fiscal Year 2025,” while another 8-K described a transition agreement with the company’s Senior Vice President, Chief Legal Officer, and Corporate Secretary, outlining continued service, compensation, and equity vesting terms. Such filings help investors track both financial performance and key governance changes.
On Stock Titan, VREX filings are updated as they are made available through EDGAR. AI-powered summaries highlight the main points of lengthy documents, helping readers quickly understand topics such as segment performance, non-GAAP reconciliations, debt and liquidity, and executive arrangements. Users can also review ownership and insider activity through forms that report transactions by officers and directors, providing an additional perspective on Varex Imaging Corporation’s regulatory record.
Varex Imaging Corporation reported the results of its 2026 annual meeting of stockholders. Stockholders representing 38,575,226 shares, about 92% of shares outstanding and eligible to vote, were present in person or by proxy, establishing a strong quorum.
All seven director nominees — Kathleen L. Bardwell, Jocelyn D. Chertoff, Timothy E. Guertin, Jay K. Kunkel, Walter M. Rosebrough, Jr., Sunny S. Sanyal and Christine A. Tsingos — were elected to serve until the 2027 annual meeting of stockholders.
Stockholders also approved on an advisory basis the compensation of the company’s named executive officers and ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year 2026.
Varex Imaging Corp director Kathleen Bardwell reported an acquisition of deferred stock units. On 02/12/2026, she received 12,331 Deferred Stock Units at a price of $0 per unit, all held as direct beneficial ownership.
Each Deferred Stock Unit converts into one share of common stock. The units vest 100% on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting after the grant date. Vested shares will be delivered upon the earlier of the third anniversary of the grant date, a change in control, or the end of Bardwell’s service for any reason.
Varex Imaging Corp director Jay K. Kunkel received a grant of 12,331 Deferred Stock Units on February 12, 2026. The grant is recorded at a price of $0 per unit and is reported as directly owned.
Each Deferred Stock Unit converts into one share of Varex common stock. The units vest 100% on the earlier of one year from the grant date or the next annual stockholder meeting after the grant. Vested shares are delivered on the earlier of the third anniversary of the grant, a change in control, or Kunkel’s termination of service for any reason.
Varex Imaging Corp director Walter M. Rosebrough Jr. received a grant of 14,947 Deferred Stock Units on February 12, 2026. These units were awarded at a price of $0 as a form of equity compensation and are held as a derivative security.
Each Deferred Stock Unit converts into one share of Varex Imaging common stock. The units vest 100% on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, and the underlying shares will be delivered on the earlier of the third anniversary of the grant, a change in control, or the director’s termination of service.
Varex Imaging Corp director Christine A. Tsingos received an equity grant of 12,331 deferred stock units on February 12, 2026. The units were awarded at a price of $0 and are held directly. Each deferred stock unit converts into one share of Varex common stock.
The deferred stock units vest 100% on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders after the grant. Vested shares will be delivered to the director on the earlier of the third anniversary of the grant date, a change in control, or her termination of service.
Varex Imaging Corp director Timothy E. Guertin reported an award of deferred stock units. On February 12, 2026, he acquired 12,331 Deferred Stock Units at a price of $0, all held directly.
Each unit converts into one share of common stock. The units vest 100% on the earlier of the one-year anniversary of the grant date or the next annual stockholders’ meeting. Vested shares will be delivered on the earlier of the third anniversary of the grant date, a change in control, or Guertin’s termination of service.
Varex Imaging Corp director Jocelyn D. Chertoff received an equity award in the form of deferred stock units. On 02/12/2026, she was granted 12,331 Deferred Stock Units at a price of $0. Each unit converts into one share of common stock.
The Deferred Stock Units vest 100% on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders after the grant. Vested shares will be delivered to her on the earlier of the third anniversary of the grant date, a change in control, or her termination of service.
Varex Imaging Corporation reported higher revenue and a small profit for the quarter ended January 2, 2026. Net revenues rose to
Industrial revenue grew to
Cash flow from operating activities was a use of
Varex Imaging Corporation reported a solid first quarter of fiscal 2026 with year-over-year growth and improved profitability. Revenue reached $209.6 million, up 5% from $199.8 million a year earlier, driven by a 17% year-over-year increase in Industrial segment revenue to $64.8 million, while Medical revenue was stable at $144.8 million.
GAAP net income attributable to Varex improved to $2.3 million, or $0.05 per diluted share, from a loss of $0.3 million, or $(0.01) per diluted share, in the prior-year quarter. Non-GAAP diluted net income per share increased to $0.19 from $0.10, and non-GAAP operating margin rose to 9.0%. Adjusted EBITDA grew to $28.5 million from $25.5 million.
Operating cash flow was a $16 million outflow, and cash, cash equivalents, and marketable securities declined to $125.6 million at quarter-end from $155.1 million at the end of fiscal 2025, primarily due to higher inventories. For the second quarter of fiscal 2026, the company expects revenue between $210 million and $225 million and non-GAAP net earnings per diluted share between $0.15 and $0.25.
Varex Imaging Corp director Jay K. Kunkel reported a routine equity award settlement. On February 9, 2026, he converted 8,483 Deferred Stock Units into 8,483 shares of common stock at a price of $0 per share, reflecting previously granted director compensation.
The Deferred Stock Units were granted on February 9, 2023, vested on February 8, 2024, and were delivered in common stock on the third anniversary of the grant date. Following this settlement, Kunkel directly holds 27,960 shares of Varex Imaging Corp common stock.